Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal Carcinoma
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 88 (1) , 17-21
- https://doi.org/10.1006/gyno.2002.6850
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Evaluation of Gemcitabine in Patients with Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology GroupGynecologic Oncology, 2000
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Gemcitabine Salvage Chemotherapy for Patients With Gynecologic Malignancies of the Ovary, Fallopian Tube, and PeritoneumAmerican Journal of Clinical Oncology, 1999
- Phase II study of gemcitabine in ovarian cancerAnnals of Oncology, 1999
- A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerAnnals of Oncology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cellsAnti-Cancer Drugs, 1991